阻断化诱导免疫细胞死亡通过使NRAS突变黑色素瘤对MEK抑制剂敏感
Jyoti Srivastava1, Vipin K Yadav2, Rachel V Jimenez1
1Moffitt Cancer Center, Tampa, FL, United States.
Cancer research
|April 27, 2025
概括
抑制化使NRAS突变黑色素瘤对MEK抑制剂敏感,诱导免疫细胞死亡和强烈的抗瘤免疫反应. 这为治疗这种侵袭性癌症亚型提供了新的策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 在15-25%的黑色素瘤中发现了激活NRAS突变.
- 这种黑色素瘤亚型对当前的治疗方法具有抗性,包括免疫疗法和RAS抑制剂.
- 新的治疗策略对于NRAS突变黑色素瘤至关重要.
研究的目的:
- 研究化在黑色素瘤进展和治疗耐药性的作用.
- 确定抑制化是否可以使NRAS突变黑色素瘤对MEK抑制剂产生敏感性.
- 探索这种联合治疗对瘤微环境和免疫反应的影响.
主要方法:
- 利用质谱测量用于全球酸盐形状分析.
- 进行了功能增加和丧失的研究,以评估蛋白质的关联.
- 采用了NRAS突变黑色素瘤的免疫能力强的小鼠模型.
- 进行了树突细胞和T淋巴细胞的共同培养实验.
主要成果:
- 抑制化使NRAS突变黑色素瘤对MEK抑制剂 (MEKi) 敏感,降低ERK-MAPK信号的调节.
- 化抑制导致关键蛋白质的脱化,包括NRAS,MEK和ERK.
- 组合疗法通过释放DAMP (例如,calreticulin,HMGB1) 诱导免疫细胞死亡 (ICD).
- 组合治疗通过增加瘤微环境中的CD8+T细胞,树突细胞和巨细胞显著增强了抗瘤免疫力.
结论:
- 化抑制是一种可行的策略,可以使NRAS突变黑色素瘤对MEKi敏感.
- 这种方法触发了ICD和强大的抗黑色素瘤免疫反应.
- 这些发现揭示了治疗目前无法治疗的NRAS突变黑色素瘤的潜在治疗漏洞.
相关概念视频
MAPK Signaling Cascades
4.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
4.9K
The Intrinsic Apoptotic Pathway
5.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.5K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K


